Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV000020180 | SCV001524515 | pathogenic | Hemolytic uremic syndrome, atypical, susceptibility to, 1 | 2019-08-23 | criteria provided, single submitter | clinical testing | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. |
Mayo Clinic Laboratories, |
RCV001843943 | SCV002103258 | pathogenic | not provided | 2022-01-04 | criteria provided, single submitter | clinical testing | PM1, PS3, PS4 |
Ce |
RCV001843943 | SCV002585170 | likely pathogenic | not provided | 2022-08-01 | criteria provided, single submitter | clinical testing | CFH: PS3, PS4:Moderate, PP2, BP4 |
Fulgent Genetics, |
RCV002490396 | SCV002791130 | likely pathogenic | Basal laminar drusen; Factor H deficiency; Hemolytic uremic syndrome, atypical, susceptibility to, 1; Age related macular degeneration 4 | 2022-04-19 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450649 | SCV004177479 | likely pathogenic | Factor H deficiency | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000020180 | SCV000040513 | not provided | Hemolytic uremic syndrome, atypical, susceptibility to, 1 | no assertion provided | literature only |